Polyrizon Ltd. Ordinary Shares PLRZ 深 滬
等待開盤 11-26 09:30:00 美东时间
0.5829
-0.097
-14.28%
華盛通- 最 高0.60
- 今 開0.60
- 成交量 58.49万股
- 最 低 0.5382
- 昨 收 0.68
- 總市值 349.12万
- 52周最高 1200.00
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.5338
- 委 比 33.33%
- 總股本 598.93万
- 歷史最高 1200.00
- 量 比 3.64
- 振 幅 9.09%
- 歷史最低 0.5382
- 每 手 1
- 風險率 149.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Polyrizon shares are trading lower after the company announced a 1-for-6 reverse stock split.
Polyrizon shares are trading lower after the company announced a 1-for-6 revers...
今天 02:32
Polyrizon Announces Positive In-Vitro Results For Its PL-16 Viral Blocker Candidate Against H1N1 Influenza
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced positive in-vitro
11-06 21:58
Polyrizon Releases Pre-Clinical Results For Its PL-14 Allergy Blocker Showing That PL-14 Effectively Blocked The Penetration Of Der P 1, A Major House Dust Mite Allergen
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced encouraging results
10-06 20:24
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Ltd. announced positive results from a pre-clinical study demonstrating the effectiveness of its PL-14 Allergy Blocker in preventing household dust mite allergen (Der p 1) penetration. After one hour, only 1.07% of the allergen passed through, with minimal penetration at two hours (1.14%) and 13.6% after four hours. The study used allergen loads tens of times higher than typical real-world exposure, suggesting strong protection. The All...
10-06 12:21
Polyrizon Advances Allergy Treatment with FDA Submission for PL-14
An announcement from Polyrizon Ltd. ( ($PLRZ) ) is now available. On September ...
09-19 20:57
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Ltd. has submitted its full pre-submission package to the FDA for its PL-14 allergy blocker, a nasal spray designed to provide long-lasting relief from allergic rhinitis by forming a physical barrier against allergens. This submission marks a significant step in the Company's regulatory strategy and addresses a critical unmet need in allergy treatment. PL-14 aims to alleviate mild allergic symptoms caused by airborne allergens such as p...
09-19 12:15
Polyrizon shares are trading higher after the company announced preclinical results for its PL-14 Allergy Blocker.
Polyrizon shares are trading higher after the company announced preclinical res...
09-12 20:38
Polyrizon shares are trading higher after the company announced it regained Nasdaq compliance.
Polyrizon shares are trading higher after the company announced it regained Nas...
08-14 23:53
Polyrizon Regains Compliance With Nasdaq Listing Requirements
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced that it has received formal confirmation from the Hearings Advisor
08-14 20:44
